Advanced Search
GUO Huimei, PAN Ling, HE Jianhui, HUA Luoming, CAO Zhixin, XUE Lei. Related Factors of Thrombosis in Patients with Myeloproliferative Neoplasms[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 958-960. DOI: 10.3971/j.issn.1000-8578.2013.10.010
Citation: GUO Huimei, PAN Ling, HE Jianhui, HUA Luoming, CAO Zhixin, XUE Lei. Related Factors of Thrombosis in Patients with Myeloproliferative Neoplasms[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 958-960. DOI: 10.3971/j.issn.1000-8578.2013.10.010

Related Factors of Thrombosis in Patients with Myeloproliferative Neoplasms

More Information
  • Received Date: December 25, 2012
  • Revised Date: April 07, 2013
  • Objective To investigate the related risk factors of thrombosis in patients with BCR/ABL negative myeloproliferative neoplasms(MPN) for clinic. Methods The JAK2V617F mutation of 104 patients with MPN was detected by allele-specific polymerase chain reaction (AS-PCR) method. Clinical features, laboratory examinations and thrombosis events of 104 patients with MPN were retrospectively studied. Univariate analysis was applied on the pathologic information and multivariate analysis was applied based on the univariate analysis. Results Seventy-one cases of JAK2V617F mutation(68.3%) and 45 cases of thrombosis (43.3%) were identifi ed in 104 patients with MPN. Univariate analysis revealed that age, hypertension, diagnosis, JAK2V617F and WBC were correlated with thrombosis (P<0.05). Multivariate analysis revealed that advanced age(≥60 years), JAK2V617F mutation and increased WBC count were independent risk factors of thrombosis (P<0.05). Conclusion  The thrombosis risk for MPN patients with advanced age, JAK2V617F mutation or increased WBC count may suffer high risk of thrombosis.
  • [1]
    Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases[J]. Lancet, 2005, 365 (9464):1054-61.
    [2]
    Antonioli E,Guglielmelli P,Poli G,et al.Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia[J].Haematologica,2008,93(1): 41-8.
    [3]
    Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera[J]. Leukemia,2 012,26(4):563-71.
    [4]
    Campbell PJ, Scott LM, Buck G, et al. Defi nition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study[J]. Lancet,2005,366(9501):1945-53.
    [5]
    De Stefano V,Rossi E, Za T,et al.JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis[J]. Am J Hematol,2011,86 (6):526-8.
    [6]
    Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera[J]. Blood,2007,109(6):2446-52.
    [7]
    Landolfi R,Di Gennaro L,Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation[J].Leukemia,2008,22(11):2020-8.
    [8]
    Carobbio A,Finazzi G,Guerini V,et al.Leukocytosia is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment,standard risk factors,and JAK2 mutation status[J].Blood,2007,109(6):2310-3.

Catalog

    Article views (1782) PDF downloads (632) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return